After a courtship of more than six months, Shire PLC on Monday won over its fellow drugmaker Baxalta in a deal valued at about US$31 billion. The combination would create a giant in the treatment of rare diseases.
Baxalta, which was spun off from Baxter International, generates a large portion of its sales from Advate, a drug for hemophilia. It also has a portfolio of plasma therapies and treatments for immune diseases.
The company initially rebuffed Shire’s offer last summer, saying it “significantly undervalued” the company.
Shire’s first proposal was an all-stock deal, worth US$30 billion when the companies disclosed their talks in August.
Under the terms of the deal announced on Monday, Shire is to pay US$45.57 in cash and stock for each Baxalta share, or a total of US$31 billion.
That price represents a 37.5 percent premium to Baxalta’s share price before Shire first announced in August that it had made a takeover approach.
Based on the 30-trading-day volume-weighted average of Shire’s stock price, however, the deal is valued at US$47.50 a share, or about US$32 billion.
Part of Shire’s ability to pay such a premium for Baxalta is tax savings.
Because Shire is based in Dublin, while Baxalta is based in Bannockburn, Illinois, outside Chicago, the combined company will be able to achieve a lower tax rate than Baxalta can as a stand-alone.
The combined company would have an estimated tax rate of 16 to 17 percent by next year, compared with Baxalta’s current rate of 23 to 24 percent, Shire said.
Shire said it expected to realize more than US$500 million in annual cost savings within the first three years after the deal closes.
Baxalta has been a stand-alone company for only six months. The drugmaker was spun off from Baxter in July last year to streamline its operations with a focus on specialty drugs.
Baxter, a medical supplies giant, still owns more than 19 percent and remains the largest shareholder, so the deal with Shire is incumbent upon its support.
“Baxter fully supports the proposed combination of Shire and Baxalta, which will create a major biotechnology company and global leader in rare diseases,” Baxter chairman and chief executive Jose Almeida said.
The Baxalta spinoff was structured in a way to avoid creating a tax burden for Baxter shareholders who received shares in the new company.
Preserving the “tax-free status” of the Baxalta spinoff was a key component of the takeover discussions, Shire chief executive Flemming Ornskov told reporters in a conference call on Monday.
He said he was “confident” the current structure of the transaction would accomplish that.
Tax considerations had helped drive a proposed US$54 billion sale of Shire to the US drugmaker AbbVie last year.
After the US Department of the Treasury announced new rules aimed at curbing inversions — when a US company acquires a foreign one to reincorporate overseas to lower its tax bill — AbbVie and Shire terminated their deal.
Shares of Baxalta closed down more than 2 percent, at US$39.10 on Monday, while Shire shares closed down more than 8 percent in London trading.
“This proposed combination allows us to realize our vision of building the leading biotechnology company focused on rare diseases,” Ornskov said in a news release.
The combined company could generate more than US$20 billion in sales by 2020, with rare disease treatments accounting for 65 percent of its annual revenue, Shire said in a news release.
The companies currently have about US$13 billion in combined sales, according to Shire.
The Baxalta transaction is expected to close by the middle of this year and is subject to shareholder and regulatory approval.
SEEKING CLARITY: Washington should not adopt measures that create uncertainties for ‘existing semiconductor investments,’ TSMC said referring to its US$165 billion in the US Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) told the US that any future tariffs on Taiwanese semiconductors could reduce demand for chips and derail its pledge to increase its investment in Arizona. “New import restrictions could jeopardize current US leadership in the competitive technology industry and create uncertainties for many committed semiconductor capital projects in the US, including TSMC Arizona’s significant investment plan in Phoenix,” the chipmaker wrote in a letter to the US Department of Commerce. TSMC issued the warning in response to a solicitation for comments by the department on a possible tariff on semiconductor imports by US President Donald Trump’s
The government has launched a three-pronged strategy to attract local and international talent, aiming to position Taiwan as a new global hub following Nvidia Corp’s announcement that it has chosen Taipei as the site of its Taiwan headquarters. Nvidia cofounder and CEO Jensen Huang (黃仁勳) on Monday last week announced during his keynote speech at the Computex trade show in Taipei that the Nvidia Constellation, the company’s planned Taiwan headquarters, would be located in the Beitou-Shilin Technology Park (北投士林科技園區) in Taipei. Huang’s decision to establish a base in Taiwan is “primarily due to Taiwan’s talent pool and its strength in the semiconductor
Industrial production expanded 22.31 percent annually last month to 107.51, as increases in demand for high-performance computing (HPC) and artificial intelligence (AI) applications drove demand for locally-made chips and components. The manufacturing production index climbed 23.68 percent year-on-year to 108.37, marking the 14th consecutive month of increase, the Ministry of Economic Affairs said. In the first four months of this year, industrial and manufacturing production indices expanded 14.31 percent and 15.22 percent year-on-year, ministry data showed. The growth momentum is to extend into this month, with the manufacturing production index expected to rise between 11 percent and 15.1 percent annually, Department of Statistics
An earnings report from semiconductor giant and artificial intelligence (AI) bellwether Nvidia Corp takes center stage for Wall Street this week, as stocks hit a speed bump of worries over US federal deficits driving up Treasury yields. US equities pulled back last week after a torrid rally, as investors turned their attention to tax and spending legislation poised to swell the US government’s US$36 trillion in debt. Long-dated US Treasury yields rose amid the fiscal worries, with the 30-year yield topping 5 percent and hitting its highest level since late 2023. Stocks were dealt another blow on Friday when US President Donald
RSS